Full-Time

Group Leader

Analytical Development

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$150k - $174kAnnually

+ Equity Component + Comprehensive Benefits

Senior

San Carlos, CA, USA

Position requires onsite presence in San Carlos, CA.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • PhD in Chemistry, Analytical Chemistry, Biochemistry, or related field with 8+ years relevant industry experience; MS or BS with 15+ years of industry experience in Pharma/ Biotech industry required.
  • Proven leadership skills.
  • Outstanding organization and planning skills.
  • Must be a strong scientific leader who can guide scientists with clear goals of developing analytical methods, and critically and skillfully review and assess analytical methods under development. May need to provide direction for troubleshooting various issues during method development.
  • Proven track record of analytical development leadership for biologics and small molecules, experience with vaccines, carbohydrate, or conjugates is a plus.
  • Extensive expertise in U/HPLC, CE, SDS-PAGE, mass spectrometry, and other analytical technologies as applied to protein analytical method development, trouble shooting and validation for GMP release and stability testing.
  • Knowledge of capillary electrophoresis and/or experience in use of such would be a plus.
  • Experience in protein, carbohydrate, and conjugates analysis is highly desired, for example hands on experience and theoretical understanding of HPAEC-PAD, HPLC/UV/FLD, SEC-LC, SEC-MALS, and colorimetric assays are highly desired.
  • Attention to detail and excellent skills in record keeping / documentation. Critical thinking and ability to analyze data.
  • Strong interpersonal skills: ability to communicate effectively both verbally and in written formats.
  • Ability to work with minimum supervision in a fast-paced, cross-functional environment and collaborate effectively with other team members. Eagerness and ability to learn and understand new concepts with ease.
Responsibilities
  • Manage R&D ADQC stability programs, such as but not limited to, providing sampling. volume forecast, coordinating with stability group on stability set-down and monitoring each stability pull-point.
  • Manage in-house routine testing, such as stability and release testing, characterization, in-process samples analysis and reference standard qualification. Responsible for the overall quality and compliance of all the testing.
  • Provide technical direction, mentorship and coaching to the analytical development team.
  • Lead the design and interpretation of experiments to analyze raw materials.
  • Keep accurate and detailed records of experiments in laboratory notebooks.
  • Summarize data and communicate to cross functional team such as stability, PD and PM.
  • Represent ADQC to attend X-Functional lab operation alignment meeting led by facility.
  • Work within a team environment and provide support to further team objectives.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA for adult use. Vaxcyte employs advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while eliciting a strong immune response. Unlike traditional cell-based methods, their approach allows for the development of broad-spectrum vaccines. Vaxcyte's goal is to provide effective vaccines that can significantly reduce the impact of bacterial infections on global health.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

19%

1 year growth

61%

2 year growth

129%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from major financial entities like Vanguard and Mutual of America Capital Management indicate strong market confidence in Vaxcyte's potential.
  • The recent $816.5 million raised through stock and warrant sales provides substantial capital for advancing their vaccine pipeline.
  • The appointment of experienced board members like John Furey can provide strategic guidance and enhance corporate governance.

What critics are saying

  • The success of Vaxcyte heavily depends on the clinical and commercial success of its lead product, VAX-24, which is still subject to regulatory approval.
  • The competitive landscape in vaccine development is intense, with numerous established players potentially overshadowing Vaxcyte's market entry.

What makes Vaxcyte unique

  • Vaxcyte leverages its proprietary XpressCF™ cell-free protein synthesis platform, which allows for more efficient and versatile vaccine production compared to traditional cell-based methods.
  • Their focus on broad-spectrum vaccines, such as VAX-24 targeting 24 strains of Streptococcus pneumoniae, sets them apart in the vaccine development landscape.
  • The FDA Breakthrough Therapy designation for VAX-24 underscores the innovative potential and clinical significance of their lead product.

Help us improve and share your feedback! Did you find this helpful?